Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics

被引:0
|
作者
Anastasia Schleiger
Madeleine Salzmann
Peter Kramer
Friederike Danne
Stephan Schubert
Christian Bassir
Tobias Müller
Hans-Peter Müller
Felix Berger
Stanislav Ovroutski
机构
[1] German Heart Center Berlin,Department of Congenital Heart Disease/Pediatric Cardiology
[2] Charité-Universitätsmedizin Berlin,Department of Pediatric Radiology
[3] Charité Universitätsmedizin Berlin,Department of Gastroenterology and Hepatology
[4] DZHK (German Center for Cardiovascular Research),Division of Cardiology, Department of Pediatrics
[5] Charité Universitätsmedizin Berlin,undefined
来源
Pediatric Cardiology | 2020年 / 41卷
关键词
Fontan-associated liver disease; Liver cirrhosis; Fontan surveillance; Fontan hemodynamics; Risk factors for FALD;
D O I
暂无
中图分类号
学科分类号
摘要
Fontan-palliated patients are at risk for the development of Fontan-associated liver disease (FALD). In this study, we performed a detailed hemodynamic and hepatic assessment to analyze the incidence and spectrum of FALD and its association with patients' hemodynamics. From 2017 to 2019, 145 patients underwent a detailed, age-adjusted hepatic examination including laboratory analysis (FibroTest®, n = 101), liver ultrasound (n = 117) and transient elastography (FibroScan®, n = 61). The median patient age was 16.0 years [IQR 14.2], and the median duration of the Fontan circulation was 10.3 years [IQR 14.7]. Hemodynamic assessment was performed using echocardiography, cardiopulmonary exercise capacity testing and cardiac catheterization. Liver ultrasound revealed hepatic parenchymal changes in 83 patients (70.9%). Severe liver cirrhosis was detectable in 20 patients (17.1%). Median liver stiffness measured by FibroScan® was 27.7 kPa [IQR 14.5], and the median Fibrotest® score was 0.5 [IQR 0.3], corresponding to fibrosis stage ≥ 2. Liver stiffness values and Fibrotest® scores correlated significantly with Fontan duration (P1 = 0.013, P2 = 0.012). Exercise performance was significantly impaired in patients with severe liver cirrhosis (P = 0.003). Pulmonary artery pressure and end-diastolic pressure were highly elevated in cirrhotic patients (P1 = 0.008, P2 = 0.003). Multivariable risk factor analysis revealed Fontan duration to be a major risk factor for the development of FALD (P < 0.001, OR 0.77, CI 0.68–0.87). In the majority of patients, hepatic abnormalities suggestive of FALD were detectable by liver ultrasound, transient elastography and laboratory analysis. The severity of FALD correlated significantly with Fontan duration and impaired Fontan hemodynamics. A detailed hepatic assessment is indispensable for long-term surveillance of Fontan patients.
引用
收藏
页码:736 / 746
页数:10
相关论文
共 50 条
  • [31] Turning to "Omics" in Understanding Fontan-Associated Liver Disease
    Kim, Yuli Y.
    Hoteit, Maarouf A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (07) : 739 - 740
  • [32] Fontan-associated liver disease: Diagnosis, surveillance, and management
    de Lange, Charlotte
    Moller, Thomas
    Hebelka, Hanna
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [33] Fontan-associated liver disease after heart transplant
    de Antonio, Ines Ponz
    Grau, Pilar Castillo
    Peinadoc, Angel Aroca
    REVISTA ESPANOLA DE CARDIOLOGIA, 2024, 77 (07): : 595 - 595
  • [34] Fontan-Associated Liver Disease: Pathophysiology, Staging, and Management
    Tellez, Luis
    Rodriguez de Santiago, Enrique
    Albillos, Agustin
    SEMINARS IN LIVER DISEASE, 2021, 41 (04) : 538 - 550
  • [35] Fontan-Associated Liver Disease: Spectrum of Disease in Children and Adolescents
    Rathgeber, Steven L.
    Guttman, Orlee R.
    Lee, Anna F.
    Voss, Christine
    Hemphill, Nicole M.
    Schreiber, Richard A.
    Harris, Kevin C.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (01):
  • [36] Evaluation of Fontan failure by classifying the severity of Fontan-associated liver disease: a single-centre cross-sectional study
    Schleiger, Anastasia
    Kramer, Peter
    Salzmann, Madeleine
    Danne, Friederike
    Schubert, Stephan
    Bassir, Christian
    Muller, Tobias
    Tacke, Frank
    Muller, Hans-Peter
    Berger, Felix
    Photiadis, Joachim
    Ovroutski, Stanislav
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 59 (02) : 341 - 348
  • [37] Fontan-associated liver disease: diagnosis by elastography and laparoscopic liver biopsy
    Koizumi, Y.
    Hirooka, M.
    Yukimoto, A.
    Imai, Y.
    Nakamura, Y.
    Watanabe, T.
    Yoshida, O.
    Tokumoto, Y.
    Higaki, T.
    Abe, M.
    Hiasa, Y.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S182 - S183
  • [38] Usefulness of serological scores in the diagnosis of Fontan-associated liver disease
    Cuadros, Marta
    Abadia, Marta
    Froilan, Consuelo
    Gonzalo, Nerea
    Romero, Miriam
    Garcia-Sanchez, Araceli
    Garcia-Samaniego, Francisco Javier
    Olveira, Antonio
    Carlos Erdozain, Jose
    Ruiz-Cantador, Jose
    Gonzalez-Garcia, Elvira Ana
    Meras, Pablo
    Merino, Carlos
    Ponz, Ines
    Rodriguez-Chaverri, Adriana
    Balbacid, Enrique
    Martin-Arranz, Maria Dolores
    Castillo, Pilar
    JOURNAL OF HEPATOLOGY, 2024, 80 : S712 - S712
  • [39] Severe Fontan-Associated Liver Disease and Its Association With Mortality
    Guerrero-Chalela, Carlos-Eduardo
    Therrien, Judith
    Grossman, Yoni
    Guo, Liming
    Liu, Aihua
    Marelli, Ariane
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (19):
  • [40] Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease
    Kogiso, Tomomi
    Ogasawara, Yuri
    Taniai, Makiko
    Shimada, Eriko
    Inai, Kei
    Tokushige, Katsutoshi
    Nakai, Yousuke
    JOURNAL OF GASTROENTEROLOGY, 2025, 60 (02) : 210 - 221